![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214348
https://endpts.com/fda-hands-chinese-drug-manufacturer-a-form-483-noting-employees-destroyed-documents/
https://www.fiercepharma.com/pharma/fda-pd-1-combo-elevar-hengrui-camrelizumab-liver-cancer
https://www.biopharmadive.com/news/hercules-hengrui-glp-1-diabetes-obesity-bain-atlas-rtw/716371/
https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html
https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-approval-of-oteseconazole-capsules-for-the-treatment-of-severe-vulvovaginal-candidiasis-vvc-in-china-301904626.html
https://www.prnewswire.com/news-releases/camrelizumab-in-combination-with-rivoceranib-apatinib-significantly-prolonged-overall-survival-and-progression-free-survival-vs-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-in-a-multinational-phase-3-trial--301621486.html